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Abstract 
 
Objective 
To compare the recurrence rates after complete response to topical treatment with either 
cidofovir or imiquimod for vulval intraepithelial neoplasia (VIN) 3. 
Design 
A prospective, open, randomised multicentre trial.   
Setting 
32 general hospitals located in Wales and England.  
Population or Sample 
180 patients were randomised consecutively between Oct 21, 2009, and Jan 11, 2013, 89 to 
cidofoovir (of whom 41 completely responded to treatment) and 91 to imiquimod (of whom 
42 completely responded to treatment).  
Methods 
After 24 weeks of treatment, complete responders were followed up at 6 monthly intervals 
for 24 months. At each visit, the Common Terminology Criteria for Adverse Events 
(CTCAE) v3.0 was assessed and any new lesions were biopsied for histology.  
Main Outcome Measures 
Time to histologically confirmed disease recurrence (any grade of VIN). 
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Results 
The median length of follow up was 18.4 months. At 18 months, more participants were 
VIN-free in the cidofovir arm: 94% (95% CI: 78.2-98.5) vs 71.6% (95% CI: 52.0-84.3) 
(univariable HR: 3.46, 95% CI: 0.95-12.60, p=0.059; multivariable HR: 3.53, 95% CI: 0.96-
12.98, p=0.057). The number of grade 2+ events was similar between treatment arms 
(imiquimod: 24/42 (57%) vs. cidofovir: 27/41 (66%), χ2=0.665, p=0.415), with no grade 4+. 
Conclusions 
Long term data indicates a trend towards response being maintained for longer following 
treatment with cidofovir compared to imiquimod, with similar low rates of adverse events for 
each drug. Adverse event rates indicated acceptable safety of both drugs 
Funding  
Cancer Research UK (CRUK/06/024). 
Keywords: 
Vulval intraepithelial neoplasia 
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VIN  
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Long term follow up 
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Trial registration: ISRCTN 34420460 (http://www.isrctn.com/ISRCTN34420460) 
 
Tweetable abstract: Long term follow up in the RT3VIN trial suggests cidofovir may 
maintain response for longer than imiquimod  
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Introduction 
Vulval Intraepithelial Neoplasia (VIN) is a chronic, premalignant condition affecting the 
vulval skin. The age-standardised incidence is approximately one per 100 000 women, with a 
peak at 30-49 years of age, and has risen over recent decades.1, 2 VIN is usually associated 
with high-risk types of human papillomavirus (HPV) (>80%), most commonly HPV 16, but 
may also be related to lichen sclerosus.3 VIN can be divided into grades 1, 2 and 3, depending 
on the proportion of the epithelium containing undifferentiated cells, with VIN 3 displaying 
full thickness neoplasia.4 Symptoms may be severe and include pain, itching and 
dyspareunia, with treatment often required on these grounds alone.5 Rates for progression to 
invasive disease are difficult to estimate, as most women undergo surgery to remove the 
disease, but may be up to 5% per year, or 1-2 % with surgery.6 Surgery is currently the 
standard treatment, but may be associated with significant morbidity5, 7 and recurrence rates 
are high (reported at 30-56%)8, 9 meaning that multiple surgeries are often required which can 
cause significant physical and psychosexual morbidity; alternative treatments are being 
sought. 
 
The RT3VIN trial published in 2014, was a randomised phase II investigating the safety and 
efficacy of two novel topical therapies, cidofovir and imiquimod, in the treatment of VIN.10 
Cidofovir is a nucleoside analogue with antiviral properties; imiquimod is an immune 
response modifying medication licenced to treat anogenital warts. The trial reported when its 
primary endpoint (biopsy proven VIN at 6 weeks post treatment) was mature. Between 21st 
October 2009 and 11th January 2013, 180 participants were enrolled to the study from 32 
general hospitals located in Wales and England. At the post-treatment assessment visit, a 
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complete proven histological response had been achieved by 46% of patients on both 
cidofovir and imiquimod.  
 
An important factor in the treatment decision making process is risk of recurrence and  
research assessing long term follow up of patients treated with cidofovir for VIN 3 is lacking. 
Imiquimod is more extensively studied, but only a few small studies have reported follow up 
data and recurrence rates vary from 0-50% with a follow up period ranging from 10–60 
months.11-18 
 
The protocol for RT3VIN included follow up of complete responders for two years to assess 
late treatment toxicity and recurrence rates. The primary objective of this paper is to compare 
the recurrence rates after complete response to topical treatment. 
 
Methods 
The trial design, treatment options, eligibility criteria, and follow-up modalities were 
previously reported in detail.10 In summary, the trial included patients with the following key 
eligibility criteria: over 16 years of age; biopsy proven VIN 3 (including visible perianal 
disease not extending into the anal canal) within the last three months (including HPV DNA 
testing in the biopsy); no early invasive disease; no pregnancy; no impaired renal function; 
and no previous failure of imiquimod or cidofovir. Patients were randomised (1:1 
minimisation with a random element (80:20) stratified by treating hospital, unifocal or multi-
focal disease, and first or recurrent disease) to receive either imiquimod or cidofovir topical 
treatment and to apply it three times a week for 24 weeks. Assessments during the treatment 
period (weeks 6, 12, 18 and 24 of treatment) included clinical assessment of lesions using 
adapted RECIST (see supplementary material in original paper 10). Patients attended for their 
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Post Treatment Assessment Visit (PTAV) 6 weeks after the end of treatment (a maximum of 
30 weeks after the start of treatment) or, if earlier, 6 weeks after a complete response or 
disease progression (using adapted RECIST) was found. Assessments at the PTAV included 
a biopsy assessment of histological response. Follow-up visits to assess recurrence rates, 
continued only for those participants who had a histological complete response at the PTAV, 
were performed at 6, 12, 18 and 24 months post complete response. These assessments 
included adverse events (National Cancer Institute's Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0), clinical examination and, if a lesion was present, a 
biopsy for histology (although HPV DNA testing was not done). The trial was registered 
(ISRCTN 34420460) and approved by a UK multicentre ethics committee and individual 
informed consent was obtained from all participants. A patient representative was involved in 
the design and management of the study. Cancer Research UK funded the trial 
(CRUK/06/024) and ensured external peer review for scientific quality but had no role in 
conducting it or writing up the results. 
 
All statistical analyses were pre-planned and conducted using Stata SE 14. A recurrence was 
defined as “new VIN” of any grade since further treatment may be administered to prevent 
progression to higher grades. Some lesions were not biopsied so their VIN status was 
unknown  (although they were noted as being either clinically suspicious or not) and some 
biopsies were inconclusive, thus a sensitivity analysis was conducted using “new lesion” 
(including those not biopsied and inconclusive biopsies) as a recurrence. We calculated time 
to recurrence from date of the PTAV to the time when a recurrence occurred. Patients who 
were recurrence free were censored at the time they were last known to be recurrence free. 
We estimated recurrence time distributions with the Kaplan-Meier method and compared 
recurrence rates with hazard ratios from Cox regression in univariable models and 
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multivariable models. In multivariable models we included the treatment effect and 
randomisation stratification variables (with centre as a shared frailty effect) which were the 
only variables thought a priori to potentially influence recurrence. We tested the proportional 
hazards assumption of each model with Cox-Snell residuals and Schoenfeld’s global test. 
 
Results  
The analysis was conducted when all complete responders (of which there were 83) had had 
their post treatment assessment visit more than 2 years ago (Figure 1). Characteristics of 
these patients are shown in Table 1. 
 
Adverse events 
There were no grade 4+ adverse events during follow up (Table 2). There was no evidence of 
a difference between trial arms in either the proportion of complete responders experiencing 
any grade 2+ adverse event during follow up (imiquimod: 24/42 (57%) vs cidofovir: 27/41 
(66%), χ2=0.665, p=0.415) or any grade 3+ during follow up (imiquimod: 3/42 (7%) vs 
cidofovir: 6/41 (15%), χ2=1.204, p=0.272). 
 
Time to recurrence 
The length of follow up was similar in each trial arm (cidofovir: median 18.2 months, 95% 
CI: 17.5-19.0; imiquimod: median 18.8 months, 95% CIs: 17.9-20.4) and was a median of 
18.4 months after the PTAV (95% CI: 18.1-19.0 overall).   
 
Table 3 shows the nature of the first new lesions and VIN found during follow up. No 
malignant lesions were found. There were no instances of VIN increasing in grade during 
follow up so first VIN represents worst VIN during follow up. 
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There was some evidence that the time to new VIN was shorter in the imiquimod arm 
(univariable HR: 3.46, 95%CI: 0.95-12.6, p=0.059) (Figure 2a, Table 4). At 18 months, 
71.6% of complete responders on imiquimod (95% CI: 52.0-84.3) and 94.0% of complete 
responders on cidofovir (95% CI: 78.2-98.5) remained VIN free. In a multivariable model, 
there was: 
a)  some evidence that imiquimod (HR 3.53, 95% CI: 0.96-13.0, p=0.057),  
b) and no evidence that either multifocal  (HR 1.80, 95% CI: 0.60-5.42, p=0.294) or 
recurrent disease prior to treatment (HR 1.36, 95% CI: 0.45-4.08, p=0.584)  
were associated with shorter time to new VIN in complete responders. In a sensitivity 
analysis we also looked at time to VIN 3 recurrences only (Table 4, Figure 2b) and found a 
similar association with imiquimod (multivariable HR 4.72, 95% CI: 0.96-23.3, p=0.056). In 
further sensitivity analyses of time to any VIN, we also included baseline HPV DNA status 
(to indicate whether the original disease was differentiated vs. usual VIN) and previous other 
anogenital neoplasia (found to be slightly imbalanced between treatment groups as shown in 
Table 1): in the univariable models, neither was found to be associated with time to new VIN 
(HPV DNA positive: HR 0.88, 95% CI: 0.19-4.05, p=0.875; previous other neoplasia: HR 
0.33, 95% CI: 0.07-1.48, p=0.147); in the multivariable model, the strength of the treatment 
effect was maintained (imiquimod HR 4.39, 95% CI: 0.87-22.3, p=0.074, n=75).  
 
We also conducted a sensitivity analysis looking at time to “new lesion”. There was some 
evidence that the time to new lesion was shorter in the imiquimod arm (univariable HR: 2.04, 
95%CI: 0.99-4.20, p=0.055) (Table 4, Figure 2c). Four complete responders in the 
imiquimod arm and 3 complete responders in the cidofovir arm had new lesions present at 
their post treatment assessment visit which explains the initial drops in proportion of patients 
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who were lesion free. At 18 months, 50% of complete responders on imiquimod (95% CI: 
33.6%-64.5%) and 69% of complete responders on cidofovir (95% CI: 51.2-82.0) remained 
lesion free. In a multivariable model, there was:  
a) some evidence that imiquimod (HR 1.9, 95% CI: 0.92-3.94, p=0.084)  
b) strong evidence that multifocal disease prior to treatment (HR 2.75, 95% CI: 1.33-
5.71, p=0.007) 
c) and no evidence that recurrent disease prior to treatment (HR 0.84, 95% CI: 0.42-
1.68, p=0.609)  
were associated with shorter time to new lesion in the complete responders. 
 
 
Discussion 
Main findings 
The long term follow up of complete responders in RT3VIN suggests a trend towards 
response being maintained for longer in patients who were given cidofovir when compared to 
imiquimod. There was no evidence of a difference in the rates of adverse events during the 
two years after assessment of initial response, there were no grade 4+ events, and the rates of 
grade 3 events were very low. At 18 months after complete response at PTAV, 71.6 % and 
94.0% of patients remained VIN free (i.e. recurrence rates of 28.4% and 6.0%) with 
imiquimod and cidofovir respectively. 
 
Strengths and limitations 
There is a lack of research investigating the long term outcome of patients treated with both 
these medications and the few studies available often present relatively small numbers or 
short duration of follow up. Regarding imiquimod, this study represents the largest with long 
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term follow up data and the findings are in line with those reported in the literature to date. A 
trial of imiquimod versus placebo found that of the 24 patients on imiquimod, 9 had a 
complete response of whom 8 (88·8%) remained VIN free after 7.3 years.16. A non-
randomised study compared imiquimod with cold knife excision and demonstrated complete 
response in 46·9% (15/32) patients treated with imiquimod of which 33·3% (5/15) had 
developed a recurrence by 60 months.13 Regarding cidofovir, the only study reporting any 
long term follow up of patients found recurrence rates of 11·1% (1/9) at 168 days but this 
study was only in  low grade intraepithelial neoplasia.19 
 
This was a Phase II study and recurrence rates were a secondary endpoint. As shown in 
Figure 1, only complete responders were followed up so selection bias may be occurring 
hence other potentially prognostic variables were included in multivariable analyses. 
Furthermore, although this research indicates that cidofovir may be superior, it is not 
currently available for topical administration and was formulated specifically for this clinical 
trial. Additionally, follow up time was relatively short - five or 10 years would provide even 
more useful data. Finally, although a tissue biopsy was required to confirm VIN 3 to establish 
eligibility for the trial at recruitment, a biopsy was not done in all cases of new lesions during 
follow up. Biopsies are painful and were sometimes declined in our study hence full data on 
VIN status was unavailable necessitating sensitivity analyses.  
 
Two methods of classification of VIN exist; both are based on histologically identifiable 
characteristics in a tissue biopsy. The first method was established in 1986 when the 
International Society for the Study of Vulvar Disease (ISSVD) developed the term VIN to 
describe the precursor lesions of vulval squamous cell carcinoma using terminology 
analogous to that used for cervical disease (CIN). This system defines classic histological 
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features to be identified and then grades the VIN based on the degree of epithelial 
involvement as VIN 1, 2 or 3. It was thought that the natural history of disease was 
progressive from VIN 1 to VIN 3 and, in some cases, to invasive cancer. Recently, use of the 
term VIN 1 has been discouraged based on the lack of evidence supporting the morphologic 
continuum of VIN 1-3 synonymous with CIN.6 The histological changes previously identified 
as VIN 1 are now thought to represent the early reactive atypia associated with new HPV 
infection and are, more often than not, reversible making labelling as a pre-malignant state 
inappropriate.4, 20-22 The classification was subsequently modified in 2004 by the ISSVD to 
recognise the two different modes of pathogenesis leading to disease; the more common 
usual VIN (uVIN) being HPV dependent and the less common differentiated VIN (dVIN), 
which is HPV independent .23 The subtypes are differentiated histologically. Histological 
features of uVIN remain the same as those used for CIN. The new terminology (uVIN, dVIN) 
has not been broadly adopted in the UK yet, with many departments still using the older 
classifications (VIN 1, 2 and 3) which is why it was used in this study. Additionally, the 
histological characteristics of dVIN being subtle and less well defined than its uVIN 
counterpart leading to increased likelihood of intra-observer variation (Preti et al. 2000). 
Hence a pragmatic decision was made to use the VIN 1, 2, 3 classification in the current 
study. In the RT3VIN trial, HPV DNA testing was performed on all biopsies of the original 
disease prior to treatment (thus can be used as a proxy for uVIN (HPV positive) and dVIN 
(HPV negative)) but it was not performed on the biopsies of recurrent disease. 
 
Interpretation 
For the purpose of comparison, the outcomes associated with surgical excision (the current 
standard of treatment) are more broadly studied. The largest study to date was a cohort of 405 
women with VIN 2+ in New Zealand in which half were followed up for at least 5 years and 
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one quarter followed up for at least 10 years.24 342 of these women had initial treatment, 
primarily either surgical excision or laser vaporization (11 patients are noted as having other 
initial treatments, including imiquimod, or unknown initial treatment). Of those who had 
initial treatment, 23% of patients had a second treatment (for recurrence or initial treatment 
failure) within 18 months. This increased to ~40% at 5 years and ~50% at 14 years. Thus the 
results generated by the present study indicate that the recurrence rates seen with cidofovir 
complete responders may be better than with surgery. 
 
Reported recurrences following surgical treatment are often based on the presumption that 
100% of the patients responded completely in the first instance. It is quite possible that these 
recurrences actually represent persistent disease following the excision, particularly in view 
of the fact that recurrences are more common in patients with positive surgical margins 24,  
but surgery probably still represents the most efficient, currently available method of 
management. However, given the obvious benefits of a topical treatment in terms of quality 
of life, future work should focus on improving the initial response to medical treatment by 
optimising therapy. Data from the translational component of the original RT3VIN trial has 
demonstrated that cidofovir and imiquimod appear to be working in two, biologically distinct, 
groups (discerned according to HPV DNA methylation levels), so patients more likely to 
respond to one treatment or the other could potentially be identified using this as a 
biomarker.25. Alternatively, a formulation combining the two medications could be 
considered. Either optimisation method could improve initial response rates using a treatment 
modality with potentially better recurrence rates.  
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Conclusion 
Cidofovir may be a better topical treatment for VIN 3 than imiquimod in terms of 
maintaining complete response. This study is the largest randomized trial to have compared 
topical treatments of VIN, the only trial to have long term follow up of VIN 3 patients treated 
with cidofovir, and represents the best available evidence for choosing alternatives to surgery. 
These data, together with other results suggesting that imiquimod and cidofovir work in 
biologically distinct subgroups, can be used to design future trials to optimise topical 
treatment to allow more women to  potentially avoid surgery. 
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Table 1. Patient characteristics of complete responders at baseline and post treatment 
assessment  
    Cidofovir (N=41) Imiquimod (N=42) 
At baseline (pre-treatment) 
Immunocompromised Yes 1 (2) 2 (5) 
No 40 (98) 40 (95) 
Smoking status 
Current 24 (59) 23 (55) 
Previous 13 (32) 10 (24) 
Never 4 (10) 9 (21) 
Disease focality Unifocal 24 (59) 20 (48) 
Multifocal 17 (41) 22 (52) 
Sum of longest lesion diameters (mm)   35 (25-45) 37 (28-60) 
Time from current diagnosis of VIN to randomisation (days) 37 (18-70) 42 (25-61) 
Recurrent VIN Yes 19 (46) 18 (43) 
No 22 (54) 24 (57) 
Time from first diagnosis of VIN to randomisation (months) 66 (27-141) 85 (22-117) 
Number of previous treatments (applicable 
to patients with recurrent disease only) 
0 0 (0) 2 (5) 
1 7 (17) 7 (17) 
2–4 10 (24) 9 (21) 
6 1 (2) 0 (0) 
Unknown 1 (2) 0 (0) 
Previous other anogenital neoplasia 
Cervical intraepithelial neoplasia 12 (29) 7 (17) 
Vaginal intraepithelial neoplasia 4 (10) 2 (5) 
Anal intraepithelial neoplasia 4 (10) 1 (2) 
None 21 (51) 31 (74) 
Missing 0 (0) 1 (2) 
HPV DNA positive 
Yes 31 (76) 32 (76) 
No 6 (15) 6 (14) 
Missing biopsy findings 4 (10) 4 (10) 
HPV 16 DNA positive 
Yes 27 (66) 26 (62) 
No 10 (24) 12 (29) 
Missing biopsy findings 4 (10) 4 (10) 
At post treatment assessment 
Age (years)    50 (45-54) 50.5 (46-57) 
Data are number of patients (%) or median (IQR). VIN=vulval intraepithelial neoplasia. 
 
 
Table 2. Adverse events during follow up 
  Cidofovir (N=41) Imiquimod (N=42) 
  Grade 1-2 Grade 3 Grade 1-2 Grade 3 
Expected adverse events n % n % n % n % 
Fatigue 11 27 4 10 14 33 0 0 
Pruritus 15 37 2 5 12 29 0 0 
Ulceration 0 0 0 0 0 0 0 0 
Pain in vulva 8 20 1 2 4 10 0 0 
Headache 5 12 0 0 4 10 3 7 
Muscle pain 6 15 0 0 9 21 0 0 
Proteinuria 0 0 0 0 1 2 0 0 
Other adverse eventsa                 
Anxiety 0 0 1 2 0 0 0 0 
Flu like symptoms 0 0 1 2 0 0 0 0 
aIncluded if at least one patient had an event of grade 3 or higher, or if grade 1–2 adverse events in more than 10% of the population were 
present in any column. No grade 4 or 5 adverse events reported. 
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Table 3. Nature of first new lesion and first VIN recurrence events 
 Cidofovir (N=41) Imiquimod (N=42) 
 n % n % 
No new lesions found during follow up 30 73 20 48 
First new lesion 
found but not 
biopsied 
Not suspicious 5 12 6 14 
Suspicious 1 2 2 5 
Unknown 0 0 2 5 
First new lesion 
found and biopsied 
VIN1 0 0 2 5 
VIN2 1 2 1 2 
VIN3 2 5 7 17 
No VIN 1 2 1 2 
Inconclusive 1 2 1 2 
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Table 4. Univariable and multivariable cox regression for time to recurrence (new lesion or new VIN) 
Variable Category N New lesion New VIN VIN3 
Univariable Multivariable  Univariable Multivariable  Univariable Multivariable 
HR 95% CIs p HR 95% CIs p HR 95% CIs p HR 95% CIs p HR 95% CIs p HR 95% CIs p 
Trial arm  Cidofovir 41                   
Imiquimod 42 2.04 0.99-
4.20 
0.055 1.9 0.92-
3.94 
0.084 3.46 0.95-
12.6 
0.059 3.53 0.96-
13.0 
0.057 3.98 0.82-
19.2 
0.086 4.72 0.96-
23.3 
0.056 
Recurrent disease 
prior to treatment  
No 46                   
Yes 37 0.78 0.39-
1.56 
0.488 0.84 0.42-
1.68 
0.609 1.16 0.39-
3.45 
0.791 1.36 0.45-
4.08 
0.584 2.01 0.50-
8.05 
0.326 2.54 0.62-
10.4 
0.194 
Focality of disease 
prior to treatment 
Unifocal 44                   
Multifocal 39 2.83 1.37-
5.85 
0.005 2.75 1.33-
5.71 
0.007 1.90 0.63-
5.70 
0.251 1.80 0.60-
5.42 
0.294 1.48 0.39-5.6 0.562 1.48 0.39-5.6 0.569 
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